GENEVA / Dec 27, 2023 / Business Wire / Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2024 J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST.
A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Connect with us on
Facebook
LinkedIn
| Last Trade: | US$92.54 |
| Daily Change: | 0.49 0.53 |
| Daily Volume: | 981,495 |
| Market Cap: | US$45.770B |
April 02, 2025 March 26, 2025 March 25, 2025 February 25, 2025 February 24, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
